ATRA
Price
$6.88
Change
+$0.27 (+4.08%)
Updated
Mar 12, 04:59 PM (EDT)
Capitalization
38.79M
FOLD
Price
$8.88
Change
-$0.00 (-0.00%)
Updated
Mar 12, 04:59 PM (EDT)
Capitalization
2.73B
56 days until earnings call
Ad is loading...

ATRA vs FOLD

Header iconATRA vs FOLD Comparison
Open Charts ATRA vs FOLDBanner chart's image
Atara Biotherapeutics
Price$6.88
Change+$0.27 (+4.08%)
Volume$6.25K
Capitalization38.79M
Amicus Therapeutics
Price$8.88
Change-$0.00 (-0.00%)
Volume$41.8K
Capitalization2.73B
ATRA vs FOLD Comparison Chart
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. FOLD commentary
Mar 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Buy and FOLD is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 13, 2025
Stock price -- (ATRA: $6.62 vs. FOLD: $8.87)
Brand notoriety: ATRA and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 32% vs. FOLD: 140%
Market capitalization -- ATRA: $38.79M vs. FOLD: $2.73B
ATRA [@Biotechnology] is valued at $38.79M. FOLD’s [@Biotechnology] market capitalization is $2.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATRA and FOLD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 5 TA indicator(s) are bullish while FOLD’s TA Score has 5 bullish TA indicator(s).

  • ATRA’s TA Score: 5 bullish, 4 bearish.
  • FOLD’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ATRA is a better buy in the short-term than FOLD.

Price Growth

ATRA (@Biotechnology) experienced а -7.15% price change this week, while FOLD (@Biotechnology) price change was -2.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.72%. For the same industry, the average monthly price growth was -6.30%, and the average quarterly price growth was -7.80%.

Reported Earning Dates

ATRA is expected to report earnings on Aug 12, 2024.

FOLD is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($2.73B) has a higher market cap than ATRA($38.8M). FOLD YTD gains are higher at: -5.839 vs. ATRA (-50.263). FOLD has higher annual earnings (EBITDA): -9.2M vs. ATRA (-123.21M). FOLD has more cash in the bank: 250M vs. ATRA (67.2M). ATRA has less debt than FOLD: ATRA (49.9M) vs FOLD (445M). FOLD has higher revenues than ATRA: FOLD (494M) vs ATRA (100M).
ATRAFOLDATRA / FOLD
Capitalization38.8M2.73B1%
EBITDA-123.21M-9.2M1,340%
Gain YTD-50.263-5.839861%
P/E RatioN/AN/A-
Revenue100M494M20%
Total Cash67.2M250M27%
Total Debt49.9M445M11%
FUNDAMENTALS RATINGS
ATRA vs FOLD: Fundamental Ratings
ATRA
FOLD
OUTLOOK RATING
1..100
566
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
9581
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (75) in the Biotechnology industry is in the same range as ATRA (77). This means that FOLD’s stock grew similarly to ATRA’s over the last 12 months.

FOLD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that FOLD’s stock grew similarly to ATRA’s over the last 12 months.

FOLD's SMR Rating (95) in the Biotechnology industry is in the same range as ATRA (100). This means that FOLD’s stock grew similarly to ATRA’s over the last 12 months.

FOLD's Price Growth Rating (81) in the Biotechnology industry is in the same range as ATRA (95). This means that FOLD’s stock grew similarly to ATRA’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that FOLD’s stock grew similarly to ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRAFOLD
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 13 days ago
72%
Declines
ODDS (%)
Bearish Trend 20 days ago
87%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DSGN5.330.46
+9.45%
Design Therapeutics
PLYA13.30-0.02
-0.15%
Playa Hotels & Resorts NV
ING19.88-0.08
-0.40%
ING Groep NV
MESA0.93-0.01
-1.06%
Mesa Air Group
FSK21.74-0.93
-4.10%
FS KKR Capital Corp